Drug approved for advanced prostate cancer
**Core Concept**
The management of advanced prostate cancer involves the use of targeted therapies and hormonal therapies to slow disease progression. One such therapy is a drug that inhibits the androgen receptor, thereby reducing the growth of cancer cells.
**Why the Correct Answer is Right**
The drug approved for advanced prostate cancer is Enzalutamide, a non-steroidal anti-androgen that selectively binds to the androgen receptor, preventing its activation and subsequent transcription of genes involved in cell proliferation. This mechanism of action leads to a decrease in tumor size and delay in disease progression.
**Why Each Wrong Option is Incorrect**
* **Option A:** Docetaxel is a chemotherapy agent used in the treatment of advanced prostate cancer, but it is not a targeted therapy like Enzalutamide.
* **Option B:** Abiraterone acetate is an irreversible inhibitor of CYP17, an enzyme involved in androgen synthesis, but it is not an androgen receptor inhibitor like Enzalutamide.
* **Option D:** Sipuleucel-T is a vaccine therapy that stimulates an immune response against prostate cancer cells, but it is not a targeted therapy like Enzalutamide.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that the choice of therapy for advanced prostate cancer depends on the patient's previous treatment history, the presence of hormone receptor status, and the presence of metastatic disease.
**Correct Answer: C. Enzalutamide**